Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (321-330 of 499) with videos related to

Pageof 50
Sort By:
Therapeutic Advances in Medical Oncology|October 27, 2023
Intra-individual qualitative and quantitative comparison of [<sup>68</sup>Ga]Ga-DOTATATE PET/CT and PET/MRIGéraldine Lens, Niloefar Ahmadi Bidakhvidi, Vincent Vandecaveye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
The New England Journal of Medicine|April 3, 2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerEric Van Cutsem, Claus-Henning Köhne, Erika Hitre, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 17, 2005
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European ConsensusVincenzo Valentini, Bengt Glimelius, Bruce D Minsky, et al.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world dataPieter Maerten, Gilles Defraene, Albert Wolthuis, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Pageof 50

Showing results (321-330 of 499) with videos related to

Sort By:
Pageof 50
Therapeutic Advances in Medical Oncology|October 27, 2023
Intra-individual qualitative and quantitative comparison of [<sup>68</sup>Ga]Ga-DOTATATE PET/CT and PET/MRIGéraldine Lens, Niloefar Ahmadi Bidakhvidi, Vincent Vandecaveye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 18, 2021
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
The New England Journal of Medicine|April 3, 2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancerEric Van Cutsem, Claus-Henning Köhne, Erika Hitre, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 17, 2005
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European ConsensusVincenzo Valentini, Bengt Glimelius, Bruce D Minsky, et al.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world dataPieter Maerten, Gilles Defraene, Albert Wolthuis, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancerEric Van Cutsem, Robert J Mayer, Stéphanie Laurent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 7, 2021
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061Eric Van Cutsem, Mayur Amonkar, Charles S Fuchs, et al.
Pageof 50